Express News | Silence Therapeutics PLC : Morgan Stanley Raises Target Price to $49.00 From $45.00
Express News | Silence Therapeutics PLC: Divesiran Was Well Tolerated
Express News | Silence Therapeutics: Divesiran Eliminated Need for Phlebotomy in All Well-Controlled Patients Following Infrequent Dosing
Express News | Silence Therapeutics Announces Positive Results From Ongoing Sanreco Phase 1 Study of Divesiran in Polycythemia Vera Patients
Express News | Silence Therapeutics: Study Demonstrated Highly Significant and Sustained Reductions in LP(a) to Week 48
Express News | Silence Therapeutics Announces Positive Topline 48-Week Data From Phase 2 Study of Zerlasiran in Patients With Elevated Lipoprotein(a)
What Silence Therapeutics Plc's (NASDAQ:SLN) P/S Is Not Telling You
6-K: Report of foreign private issuer (related to financial reporting)
Express News | Corrected-Silence Therapeutics Files for Resale of up to 5.71 Mln American Depositary Shares (Not 'shares') by Selling Securityholders - SEC Filing
Express News | Silence Therapeutics PLC Files for Resale of up to 5.71 Mln Shares by the Selling Securityholders - SEC Filing
Silence Therapeutics Plc's (NASDAQ:SLN) Market Cap Touched US$1.1b Last Week, Benefiting Both Retail Investors Who Own 27% as Well as Institutions
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects With Elevated Lipoprotein(a)
Analysts Are Upgrading Silence Therapeutics Plc (NASDAQ:SLN) After Its Latest Results
Silence Therapeutics Plc (NASDAQ:SLN) Q4 2023 Earnings Call Transcript
Recursion Pharmaceuticals (RXRX) Surges 13.8%: Is This an Indication of Further Gains?
Optimistic Investors Push Silence Therapeutics Plc (NASDAQ:SLN) Shares Up 26% But Growth Is Lacking
Insiders the Biggest Winners as Silence Therapeutics Plc's (NASDAQ:SLN) Market Cap Rises to US$736m
All You Need to Know About Silence Therapeutics PLC Sponsored ADR (SLN) Rating Upgrade to Strong Buy
Does Silence Therapeutics PLC Sponsored ADR (SLN) Have the Potential to Rally 187.05% as Wall Street Analysts Expect?
Optimistic Investors Push Silence Therapeutics Plc (NASDAQ:SLN) Shares Up 65% But Growth Is Lacking
No Data